Beta Drugs Ltd.

₹2,064.9

-40.3 (-1.9%)

BETA Share Price

Pharmaceuticals & Biotechnology

As on September 16, 2026

SectorNA

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,19,250 Cr

P/E Ratio49.14

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,096.4	Bearish
10-DMA	2,136.01	Bearish
20-DMA	2,204.95	Bearish
50-DMA	2,291.68	Bearish
100-DMA	1,944.88	Bullish
200-DMA	1,671.51	Bullish

Historical Performance

1 Year

13.6%

3 Years

109.3%

5 Years

431.7%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,624	2,957	2,271	1,838	1,161
Total Expenditure	2,878	2,357	1,740	1,411	914
Other Income	64	14	8	8	5
Operating Profit	810	614	539	435	252
Interest	70	28	24	19	24
Depreciation	125	98	104	73	69
Profit Before Tax	570	488	411	343	160
Consolidated Net Profit	424	364	307	248	117
Adjusted EPS	42	36	30	25	12

Compounded Sales Growth

10 Years:48.3

5 Years:31.9

3 Years:14.5

TTM:4.1

Compounded Profit Growth

10 Years:44.4

5 Years:35.1

3 Years:11.3

TTM:3.1

Stock Price CAGR

10 Years:N/A

5 Years:40.5

3 Years:27.9

TTM:13.4

Return on Equity

10 Years:N/A

5 Years:11.6

3 Years:30.4

last year:42

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	101	96	96	96	96
Total Reserves	1,870	1,475	1,133	827	590
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,346	109	113	159	149
Other Current Liabilities	215	176	95	86	78
Short Term Borrowings	57	50	91	48	35
Total Liabilities	4,451	2,624	2,039	1,630	1,201
Capital Work in Progress	---	---	---	---	28
Long Term Loans & Advances	141	102	60	44	43
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	307	294	210	175	57
Total Current Assets	3,417	1,876	1,344	1,028	713
Total Assets	4,451	2,624	2,039	1,630	1,201
Adjusted Book Value	195	156	128	96	71

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 49.14, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 27.9%, indicating sustained price appreciation.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹810 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹3624 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1134093.1

No. of Shares: 549 (Approx)

Performance:13.4%

134093.1

NIFTY Performance: -8.3%

1 day Top Gainers